Wuhan Jinyintan Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430023, China.
Hubei Cancer Hospital, Tongji Medical College, HUST, Wuhan 430079, China.
Biomed Pharmacother. 2023 Dec;168:115674. doi: 10.1016/j.biopha.2023.115674. Epub 2023 Oct 7.
Sepsis, the foremost contributor to mortality in intensive care unit patients, arises from an uncontrolled systemic response to invading infections, resulting in extensive harm across multiple organs and systems. Recently, S100A8/A9 has emerged as a promising biomarker for sepsis and sepsis-induced organ injury, and targeting S100A8/A9 appeared to ameliorate inflammation-induced tissue damage and improve adverse outcomes. S100A8/A9, a calcium-binding heterodimer mainly found in neutrophils and monocytes, serves as a causative molecule with pro-inflammatory and immunosuppressive properties, which are vital in the pathogenesis of sepsis. Therefore, improving our comprehension of how S100A8/A9 acts as a pathological player in the development of sepsis is imperative for advancing research on sepsis. Our review is the first-to the best of our knowledge-to discuss the biology of S100A8/A9 and its release mechanisms, summarize recent advances concerning the vital roles of S100A8/A9 in sepsis and the consequential organ damage, and underscore its potential as a promising diagnostic biomarker and therapeutic target for sepsis.
脓毒症是重症监护病房患者死亡的主要原因，它是由机体对入侵性感染的失控性全身反应引起的，导致多个器官和系统广泛受损。最近，S100A8/A9 已成为脓毒症和脓毒症引起的器官损伤的有前途的生物标志物，靶向 S100A8/A9 似乎可以改善炎症引起的组织损伤并改善不良结局。S100A8/A9 是一种主要存在于中性粒细胞和单核细胞中的钙结合二聚体，作为一种具有促炎和免疫抑制特性的致病分子，在脓毒症的发病机制中至关重要。因此，深入了解 S100A8/A9 如何作为一种病理性介质在脓毒症的发展中发挥作用，对于推进脓毒症的研究至关重要。据我们所知，我们的综述是首次讨论 S100A8/A9 的生物学及其释放机制，总结 S100A8/A9 在脓毒症及相关器官损伤中的重要作用的最新进展，并强调其作为脓毒症有前途的诊断生物标志物和治疗靶点的潜力。
